<DOC>
	<DOCNO>NCT00002866</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor G-CSF may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase I/II trial study effectiveness docetaxel epirubicin without G-CSF treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Docetaxel Epirubicin With Without G-CSF Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose recommended phase II dose docetaxel combination epirubicin filgrastim ( G-CSF ) first-line therapy woman metastatic breast cancer ( phase II close 03/27/2000 ) . II . Determine pharmacokinetic profile docetaxel epirubicin patient . III . Evaluate toxicity regimen give recommend phase II dose . IV . Determine response rate duration response patient treat regimen . OUTLINE : This multicenter , dose-escalation study epirubicin docetaxel . Patients receive epirubicin IV 15 minute follow docetaxel IV 60 minute day 1 . Patients also receive filgrastim ( G-CSF ) subcutaneously day 4-13 . Treatment continue every 3 week least 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos epirubicin docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose least 2 6 patient experience dose-limiting toxicity . Additional patient accrue receive treatment recommend phase II dose ( phase II close 03/27/2000 ) . Patients follow 1 month every 3 month survival . PROJECTED ACCRUAL : Approximately 15-20 patient accrue within 4-5 month phase I portion study . A total 15-30 patient accrue within 7-8 month phase II portion study ( close 03/27/2000 ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm breast cancer Newly diagnose progressive metastatic disease least 1 metastatic target lesion No known clinical brain leptomeningeal metastasis Phase I entry : Measurable and/or evaluable disease indicator lesion outside prior radiotherapy field Phase II entry : ( close 03/27/2000 ) Bidimensionally measurable disease indicator lesion outside prior radiotherapy field At least 1 x 1 cm chest xray At least 2 x 2 cm CT scan ultrasound Skin lesion node least 1 x 1 cm No boneonly lesion Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 16 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Hematopoietic : Absolute granulocyte count least 2,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great upper limit normal ( ULN ) AST/ALT great 1.5 time ULN Alkaline phosphatase great 2.5 time ULN ( great 5.0 time ULN AST/ALT normal ) Renal : Creatinine great 1.5 time ULN Cardiovascular : Left ventricular ejection fraction least 50 % rest MUGA echocardiogram No congestive heart failure No angina pectoris ( even control ) No myocardial infarction within past year No uncontrolled arrhythmia No uncontrolled hypertension Other : No active infection No grade 2 great symptomatic peripheral neuropathy No significant neurologic psychiatric disorder , include dementia seizures No peptic ulcer , unstable diabetes mellitus , contraindication dexamethasone No prior malignancy except nonmelanomatous skin cancer excise carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception Geographically accessible PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent supportive colonystimulating factor ( e.g. , filgrastim ( G CSF ) ) ( Prophylactic treatment second step phase I allow ) Chemotherapy : Phase I patient : At least 12 month since prior adjuvant chemotherapy Prior neoadjuvant chemotherapy allow Prior cumulative dose doxorubicin great 300 mg/m2 Prior cumulative dose epirubicin great 500 mg/m2 If epirubicin dose level least 90 mg/m2 : Prior cumulative dose doxorubicin great 200 mg/m2 Prior cumulative dose epirubicin great 300 mg/m2 Phase II patient : ( close 03/27/2000 ) No prior neoadjuvant adjuvant chemotherapy regimen cyclophosphamide , methotrexate , fluorouracil , doxorubicin cyclophosphamide give maximum 4 course All patient : No prior chemotherapy metastatic disease No prior taxanes Endocrine therapy : Prior hormonal therapy adjuvant and/or metastatic setting allow subsequent disease progression No 2 prior hormonal therapy regimens metastatic disease No concurrent corticosteroid ( except premedication hypersensitivity reaction ) Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy ( unless single fraction palliation ) Concurrent local palliative radiotherapy control bone pain reason curative intent allow Concurrent wholebrain radiotherapy brain metastasis allow No concurrent radiotherapy sole measurable lesion Surgery : Not specify Other : No concurrent investigational drug anticancer therapy No concurrent preventive IV antibiotic</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>neutropenia</keyword>
</DOC>